KALVISTA PHARMACEUTICALS INC(NASDAQ:KALV) stock News

KALV Latest News, Press Relases and Analysis

All

Press Releases

6 days ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 20th German Allergy Congress

7 days ago - By: KalVista Pharmaceuticals, Inc.

KalVista Prices Upsized Offering of $125.0 Million of 3.250% Convertible Senior Notes Due 2031

13 days ago - By: Stocktwits - Mentions: VFMO VTWG

KalVista Pharmaceuticals’ Hereditary Angioedema Drug Approved In EU, Switzerland: Retail Sees Stock Rallying To $22 In A Year

22 days ago - By: Benzinga

KalVista Pharma's Earnings: A Preview

8 days ago - By: Benzinga - Mentions: DYAI KPTI ICU SXTC ...

12 Health Care Stocks Moving In Wednesday's After-Market Session

8 days ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Announces Proposed Offering of $110.0 Million of Convertible Senior Notes

13 days ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY® (sebetralstat), First and Only Oral On-Demand Treatment for Hereditary Angioedema

21 days ago - By: The Motley Fool

KalVista Posts 154% Expense Jump in Q1

21 days ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Quarter Financial Results

a month ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals to Provide Operational Update and Fiscal Quarter Financial Results on September 11, 2025

a month ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

a month ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2025

2 months ago - By: Metagenomi, Inc. - Mentions: MGX

Metagenomi Appoints Laurence Reid, PhD to its Board of Directors

2 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Announces Maintenance of Orphan Designation for Sebetralstat in European Union

2 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks

3 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema

3 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results

3 months ago - By: Yahoo Finance - Mentions: VZ

KalVista price target raised to $37 from $22 at BofA

3 months ago - By: Stocktwits - Mentions: VFMO IWMW

KalVista Stock Soars Pre-Market On FDA Approval For Drug In Treating Swelling Disorder: Retail’s Elated

3 months ago - By: Investor's Business Daily

KalVista Ends Its Unexpectedly Messy Path To Approval In HAE Treatment

3 months ago - By: Bloomberg

KalVista Shares Surge as FDA Approves New Drug After Delay

3 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema

3 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada

3 months ago - By: Investor's Business Daily - Mentions: GSK

KALVISTA PHARMACEUTICALS INC (KALV) Stock News

KALV Latest News, Press Relases and Analysis

KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 20th German Allergy Congress

KalVista Prices Upsized Offering of $125.0 Million of 3.250% Convertible Senior Notes Due 2031

KalVista Pharmaceuticals’ Hereditary Angioedema Drug Approved In EU, Switzerland: Retail Sees Stock Rallying To $22 In A Year

KalVista Pharma's Earnings: A Preview

12 Health Care Stocks Moving In Wednesday's After-Market Session

KalVista Pharmaceuticals Announces Proposed Offering of $110.0 Million of Convertible Senior Notes

KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY® (sebetralstat), First and Only Oral On-Demand Treatment for Hereditary Angioedema

KalVista Posts 154% Expense Jump in Q1

KalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Quarter Financial Results

KalVista Pharmaceuticals to Provide Operational Update and Fiscal Quarter Financial Results on September 11, 2025

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2025

Metagenomi Appoints Laurence Reid, PhD to its Board of Directors

KalVista Pharmaceuticals Announces Maintenance of Orphan Designation for Sebetralstat in European Union

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks

KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema

KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results

KalVista price target raised to $37 from $22 at BofA

KalVista Stock Soars Pre-Market On FDA Approval For Drug In Treating Swelling Disorder: Retail’s Elated

KalVista Ends Its Unexpectedly Messy Path To Approval In HAE Treatment

KalVista Shares Surge as FDA Approves New Drug After Delay

KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada

How KalVista Pharma Is Taking On A Rare But Deadly Disease